Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We investigated the safety and neuroregenerative potential of an adeno-associated virus (AAV2) containing human glial cell line-derived neurotrophic factor (GDNF) in an MPTP primate model of Parkinson's disease. Dopaminergic function was evaluated by positron emission tomography with 6-[(18)F]fluoro-l-m-tyrosine (FMT) before and after AAV2-GDNF or phosphate-buffered saline infusion bilaterally into the putamen. FMT uptake was significantly increased bilaterally in the putamen of AAV2-GDNF but not phosphate-buffered saline-treated animals 6 months after infusion, indicating increased dopaminergic activity in the nigrostriatal pathways. AAV2-GDNF-treated animals also showed clinical improvement without adverse effects. These findings are consistent with our previous report in aged nonhuman primates that showed evidence of enhanced use of striatal dopamine and dopaminergic nigrostriatal innervation. Clinical improvement and evidence of functional recovery in the nigrostriatal pathway, and the absence of adverse effects, support the safety of this approach for the delivery of GDNF over a 6-month period.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596 · cited 3×
“…Parkinsonian subjects recruited for the phase 1 and 2 clinical trials of AAV2-NTN (CERE-120) were enrolled at a stage of the disease (stage 3 on the Hoehn and Yahr scale) in which substantial loss of nigral innervation of the striatum had been present for at least 5 years (Marks et al. , 2008).”
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 4×
“We have published extensively on the use of 6-[ 18 F]fluoro-l - m -tyrosine (FMT)-PET to measure dopaminergic function in the human and primate brains (Jordan et al. , 1997; Eberling et al. , 1998, 2000, 2004, 2007, 2008; Oiwa et al. , 2003).”
InfluentialSelf-citationSlevin, J. T., Gash, D. M., Smith, C. D., Gerhardt, G. A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R., & Young, A. B. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.4.614 · Cited by 173
Hadaczek, P., Forsayeth, J., Mirek, H., Munson, K., Bringas, J., Pivirotto, P., L McBride, J., Davidson, B. L., & Bankiewicz, K. S. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.151 · Cited by 90
Self-citation
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Stem cell technology for neurodegenerative diseases
Lunn, J. S., Sakowski, S. A., Hur, J., & Feldman, E. L. (2011) · Annals of Neurology · doi:10.1002/ana.22487 · Cited by 272
Exosomes and stem cells in degenerative disease diagnosis and therapy
Chang, Y.-H., Wu, K.-C., Harn, H.-J., Lin, S.-Z., & Ding, D.-C. (2018) · Cell Transplantation · doi:10.1177/0963689717723636 · Cited by 159
Su, X., Kells, A. P., Salegio, E. A., Richardson, R. M., Hadaczek, P., Beyer, J., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.114 · Cited by 82
Self-citationT2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery
Richardson, R. M., Gimenez, F., Salegio, E. A., Su, X., Bringas, J., Berger, M. S., & Bankiewicz, K. S. (2011) · Neurosurgery · doi:10.1227/neu.0b013e318217217e · Cited by 38
Self-citation
Metadata
- Authors
- Eberling, J. L., Kells, A. P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2009-05
- Volume
- 20
- Issue
- 5
- Pages
- 511-518
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W1971053395
- Cited by
- 95
- References
- 5
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. https://app.cochat.ai/papers/10.1089/hum.2008.201
- The paper
- Eberling, J. L., Kells, A. P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H. J., Forsayeth, J., & Bankiewicz, K. S. (2009). Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Human Gene Therapy. https://doi.org/10.1089/hum.2008.201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.